Radiation and immunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of targeted radiation (SBRT) and immunotherapy for people with esophageal cancer that has spread to a few spots in the body. The goal is to see if this approach helps control the cancer and improves your well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have esophageal cancer (adenocarcinoma or squamous cell carcinoma) that has spread to up to 5 places outside the esophagus, in up to 3 organs.
- You are generally active and able to care for yourself (but not necessarily working full-time).
- Your overall health and organ function (like blood counts, liver and kidney function) are within limits as checked by blood tests.
- You have not had progression of your esophageal cancer after standard chemotherapy plus a PD-1 inhibitor (like immunotherapy).
- You agree to use highly effective birth control if you or your partner could become pregnant, and also follow restrictions on breastfeeding and sperm donation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
This trial tests a combination of targeted radiation (SBRT) and an immunotherapy drug (AK104) for people with esophageal squamous cell cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.